Capecitabine/Docetaxel (XT): Superior Response Rate and TTP

1
Capecitabine/Docetaxel (XT) Superior Response
Rate and TTP
1.0 0.8 0.6 0.4 0.2 0.0
Response rates XT 42 docetaxel 30
p 0.006
XT (n255) docetaxel (n256)
Estimated probability
Hazard ratio 0.652 Log-rank p 0.0001
4.2
6.1
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
Time (months)
Source OShaughnessy J et al. Superior survival
with capecitabine plus docetaxel combination
therapy in anthracycline-pretreated patients with
advanced breast cancer Phase III trial results.
J Clin Oncol 200220(12)2812-23. Reprinted with
permission from the American Society of Clinical
Oncology. Abstract